Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act
This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a "priority antimicrobial product." (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.